These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25777753)

  • 21. Vasculopathy in scleroderma.
    Asano Y; Sato S
    Semin Immunopathol; 2015 Sep; 37(5):489-500. PubMed ID: 26152638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic sclerosis.
    Asano Y
    J Dermatol; 2018 Feb; 45(2):128-138. PubMed ID: 29226387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone Marrow-Derived Mesenchymal Stem Cells Expressing Thioredoxin 1 Attenuate Bleomycin-Induced Skin Fibrosis and Oxidative Stress in Scleroderma.
    Jiang M; Yu Y; Luo J; Gao Q; Zhang L; Wang Q; Zhao J
    J Invest Dermatol; 2017 Jun; 137(6):1223-1233. PubMed ID: 28132855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenic roles of B lymphocytes in systemic sclerosis.
    Yoshizaki A
    Immunol Lett; 2018 Mar; 195():76-82. PubMed ID: 29307688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrogenesis, novel lessons from animal models.
    De Langhe E; Lories R
    Semin Immunopathol; 2015 Sep; 37(5):565-74. PubMed ID: 26141608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Animal models of scleroderma.
    Lakos G; Takagawa S; Varga J
    Methods Mol Med; 2004; 102():377-93. PubMed ID: 15286396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis.
    Bei Y; Hua-Huy T; Nicco C; Duong-Quy S; Le-Dong NN; Tiev KP; Chéreau C; Batteux F; Dinh-Xuan AT
    Exp Lung Res; 2016; 42(1):44-55. PubMed ID: 26873329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights into CD4(+) T cell abnormalities in systemic sclerosis.
    Liu M; Wu W; Sun X; Yang J; Xu J; Fu W; Li M
    Cytokine Growth Factor Rev; 2016 Apr; 28():31-6. PubMed ID: 26724976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
    Yanaba K
    J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting interferons as a strategy for systemic sclerosis treatment.
    Ciechomska M; Skalska U
    Immunol Lett; 2018 Mar; 195():45-54. PubMed ID: 29106987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Connective tissue diseases: Adipocyte-myofibroblast transition: linking intradermal fat loss to skin fibrosis in SSc.
    Onuora S
    Nat Rev Rheumatol; 2015 Feb; 11(2):63. PubMed ID: 25561364
    [No Abstract]   [Full Text] [Related]  

  • 32. Animal models in systemic sclerosis.
    Rogai V; Lories RJ; Guiducci S; Luyten FP; Matucci Cerinic M
    Clin Exp Rheumatol; 2008; 26(5):941-6. PubMed ID: 19032835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Murine animal models of systemic sclerosis.
    Jimenez SA; Christner PJ
    Curr Opin Rheumatol; 2002 Nov; 14(6):671-80. PubMed ID: 12410090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New pathogenic and therapeutic concepts in systemic sclerosis.
    Hügle T; Huigens CA; van Laar JM
    Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.
    Noda S; Asano Y; Nishimura S; Taniguchi T; Fujiu K; Manabe I; Nakamura K; Yamashita T; Saigusa R; Akamata K; Takahashi T; Ichimura Y; Toyama T; Tsuruta D; Trojanowska M; Nagai R; Sato S
    Nat Commun; 2014 Dec; 5():5797. PubMed ID: 25504335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse.
    Servettaz A; Goulvestre C; Kavian N; Nicco C; Guilpain P; Chéreau C; Vuiblet V; Guillevin L; Mouthon L; Weill B; Batteux F
    J Immunol; 2009 May; 182(9):5855-64. PubMed ID: 19380834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Systemic sclerosis--pathogenesis, clinical manifestations and treatment].
    Radić M; Kaliterna DM; Fabijanić D; Radić J
    Lijec Vjesn; 2010; 132(5-6):162-8. PubMed ID: 20677623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Antifibrotic Effect of α2AP Neutralization in Systemic Sclerosis Dermal Fibroblasts and Mouse Models of Systemic Sclerosis.
    Kanno Y; Shu E; Kanoh H; Seishima M
    J Invest Dermatol; 2016 Apr; 136(4):762-769. PubMed ID: 26743600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cell abnormalities in systemic sclerosis with a focus on Th17 cells.
    Brembilla NC; Chizzolini C
    Eur Cytokine Netw; 2012; 23(4):128-39. PubMed ID: 23360781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intradermal Injections of Bleomycin to Model Skin Fibrosis.
    Yamamoto T
    Methods Mol Biol; 2017; 1627():43-47. PubMed ID: 28836193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.